A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib
Moran, Teresa, Palmero, Ramón, Provencio, Mariano, Insa, Amelia, Majem, Margarita, Reguart, Noemí, Bosch-Barrera, Joaquim, Isla, Dolores, Costa, Enric Carcereny, Lee, Chooi, Puig, Marta, Kraemer, SandVolume:
108
Langue:
english
Journal:
Lung Cancer
DOI:
10.1016/j.lungcan.2017.03.009
Date:
June, 2017
Fichier:
PDF, 431 KB
english, 2017